Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Product Launch

Biocon Product Launch

Biocon Limited has commercially launched Bosaya and Aukelso, its interchangeable denosumab biosimilars, in the United States. These products target the $5 billion U.S. market for osteoporosis and bone metastasis treatments. This strategic expansion strengthens Biocon's global biosimilars portfolio and provides affordable treatment options for over 10 million patients.

Key figures
Value₹46,500 Cr
Source

BSE filing, NSE: BIOCON. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Biocon Ltd: key numbers

Share price
₹350.70
Market cap
₹57,153 Cr
Revenue (annual)
₹16,927 Cr
Net profit (annual)
₹385.6 Cr
P/E (TTM)
115.4×Sector 46.1×
Promoter holding
44.68%+0.00% QoQ
FII holding
8.64%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Biocon Ltd

All →
08:25 IST BSE
Partnership

Biocon Partnership

Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.

From
Genentech

Other product launch announcements

All →